First Time Loading...
C

China National Accord Medicines Corp Ltd
SZSE:000028

Watchlist Manager
China National Accord Medicines Corp Ltd
SZSE:000028
Watchlist
Price: 38.42 CNY -1.44% Market Closed
Updated: May 21, 2024

China National Accord Medicines Corp Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

China National Accord Medicines Corp Ltd
Interest Income Expense Peer Comparison

Comparables:
1099
601607
600998
C
600511
000963

Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
C
China National Accord Medicines Corp Ltd
SZSE:000028
Interest Income Expense
¥27.4m
CAGR 3-Years
-47%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Sinopharm Group Co Ltd
HKEX:1099
Interest Income Expense
-¥3.1B
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
-8%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Interest Income Expense
-¥1.1B
CAGR 3-Years
-79%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Interest Income Expense
-¥1.2B
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
-14%
C
China National Medicines Corp Ltd
SSE:600511
Interest Income Expense
¥526.1m
CAGR 3-Years
25%
CAGR 5-Years
26%
CAGR 10-Years
23%
Huadong Medicine Co Ltd
SZSE:000963
Interest Income Expense
-¥248.5m
CAGR 3-Years
-46%
CAGR 5-Years
-23%
CAGR 10-Years
-20%

See Also

What is China National Accord Medicines Corp Ltd's Interest Income Expense?
Interest Income Expense
27.4m CNY

Based on the financial report for Mar 31, 2024, China National Accord Medicines Corp Ltd's Interest Income Expense amounts to 27.4m CNY.

What is China National Accord Medicines Corp Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-33%

Over the last year, the Interest Income Expense growth was -55%. The average annual Interest Income Expense growth rates for China National Accord Medicines Corp Ltd have been -47% over the past three years , -33% over the past five years .